Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288559 · ClinicalTrials.gov registry record · Phase 2
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
A Phase 2 study of Geographic Atrophy, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT02288559: Completed Phase 2 study of Geographic Atrophy, sponsored by Genentech.
NCT02288559 is a Phase 2 study of Geographic Atrophy that has completed, run by Genentech. The registered enrollment target is 96 participants, below the 218-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288559, a Phase 2 study of Geographic Atrophy, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A safety run-in assessment will be conducted prior to initiating enrollment in the randomized study.
Primary Outcome
GA or the death of photoreceptors and surrounding cells in the retina, is a common condition in participants with age-related macular degeneration (AMD). The death of these photoreceptors results in lesions that cause vision loss. The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). BCVA=best correcte
Conditions Studied
Interventions
- OTHER Sham
- DRUG Lampalizumab
Study Locations (20)
California
- Retinal Diagnostic Center - Campbell
- The Retina Partners - Encino
- Loma Linda University - Loma Linda
- San Diego Retina Associates - Oceanside
- West Coast Retina Medical Group - San Francisco
- California Retina Consultants - Santa Barbara
Florida
- Florida Eye Microsurgical Inst - Boynton Beach
- National Ophthalmic Research Institute - Fort Myers
- Florida Eye Associates - Melbourne
- Retina Care Specialists - Palm Beach Gardens
- Retina Specialty Institute - Pensacola
Arizona
- Barnet Dulaney Perkins Eye Center - Mesa
- University of Arizona; Banner University Medical, Department of Opthalmology - Tucson
Arkansas
- Northwest Arkansas Retina Associates - Springdale
Colorado
- Colorado Retina Associates, PC - Golden
Illinois
- Rush University Medical Center - Chicago
Iowa
- Wolfe Eye Clinic - West Des Moines
Maryland
- Elman Retina Group - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2015-03-30 |
| Est. Completion | 2017-06-02 |
| Phase | Phase 2 |
What the finished NCT02288559 record still lists
NCT02288559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 218-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT02288559 names 20 study sites across 10 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02288559 about?
NCT02288559 is a clinical study titled "A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy". This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related mac...
What is the current status of trial NCT02288559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2015-03-30. Estimated completion is 2017-06-02.
What conditions does trial NCT02288559 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT02288559?
The interventions under investigation include: Sham (OTHER), Lampalizumab (DRUG).
Who is sponsoring clinical trial NCT02288559?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02288559 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02288559's enrollment target sits among peer trials
96 16th of 27 higher than 12 of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI